Medical Wipe BEP Template for ISO 10993-1

“Medical Wipe” Is Not One Regulatory Category

The label medical wipe can hide very different products. A wipe may contact intact patient skin, clean a wound area, prepare skin before a procedure, clean or disinfect a reusable medical device, or simply clean a non-medical surface. FDA explains that intended use can place disposable wipes under different regulatory authorities: cosmetic cleansing wipes, therapeutic wipes, surface disinfectants and general cleansing products are not regulated in the same way.

This distinction is the first BEP decision. A product name or marketing category cannot establish the biological-evaluation scope. Document the intended purpose, claims, target users, use environment, target markets and all contact pathways before selecting endpoints or tests.

When ISO 10993-1 Belongs in the Evaluation

ISO 10993-1:2025 provides a risk-management framework for evaluating biological safety of medical devices that directly or indirectly contact the human body. It does not create a universal wipe test battery. Within that standard, non-patient user contact is addressed when the medical device is intended for personal protection. Other healthcare-worker exposure may still require evaluation under device-specific regulatory controls or occupational-safety requirements, but it should not automatically be presented as ISO 10993-1 scope.

For FDA submissions, the biological evaluation should address the final finished device, not just a list of raw materials. FDA's biocompatibility basics specifically direct attention to manufacturing, processing, sterilization and residuals, as well as the nature, type, frequency and duration of contact. The exact standard, guidance and recognition conditions must be checked for the target market at the time of the evaluation.

Map Every Exposure Pathway

A useful BEP makes exposure visible before it evaluates evidence. Depending on the intended use, the contact map may include:

• Patient contact with the wipe: intact skin, breached or compromised surface, wound, mucosal tissue, or another defined site.
• Applicable non-patient user exposure: contact when the device is intended for personal protection, or when device-specific controls require user-biocompatibility evidence. Other routine worker exposure may require a separate occupational-safety assessment.
• Patient contact through a processed device: residues transferred by the wipe may remain on an instrument or device that later contacts the patient.
• Indirect contact: substances may enter a fluid path or transfer from a processed surface even when the wipe itself never touches the patient.
• Cumulative contact: repeated wiping, multiple-use cycles, or repeated exposure to the processed device may change the total dose and biological question.

Use the contact-classification guide to structure contact nature, duration and frequency. Do not force multiple exposure routes into a single simplified label when separate patient and applicable user-safety questions are present.

Define the Final Finished Wipe System

The evaluation should describe the marketed wipe as a system. Relevant attributes can include the substrate and its additives; the complete liquid formulation and concentration ranges; preservatives, surfactants, solvents and processing aids; liquid loading; manufacturing and sterilization; packaging interactions; shelf life; in-use storage and dry-out; and any substances transferred to the patient or another device.

Supplier declarations can support this work, but they do not automatically establish final-product safety. A formulation change, new substrate supplier, altered loading range, packaging change, aging effect or revised application instruction can change exposure even when the headline ingredients appear unchanged.

Medical-Wipe BEP Structure: What to Include

The free editable Word template follows these 11 sections. Replace the prompts, expand the tables and record unresolved questions with an owner and due date; the completed content must remain device-specific.

1. Scope and document control: product, variants, markets, document owner, approvals and revision status.
2. Intended purpose and product determination: users, patients, claims, environment, regulatory status and applicable pathways.
3. Final finished wipe description: substrate, formulation, loading, processing, packaging, shelf life and use conditions.
4. Contact and exposure map: patient, user and processed-device routes, including frequency, duration and cumulative exposure.
5. Materials and manufacturing information: composition, suppliers, formulation ranges, impurities, residuals and relevant process inputs.
6. Biological hazards and endpoint questions: risks derived from actual exposure, not a copied table.
7. Existing evidence: supplier data, formulation knowledge, prior testing, literature, clinical or post-market information, with applicability limits.
8. Chemistry and toxicological strategy: transferred residues, extractables, exposure estimation and when toxicological assessment is needed.
9. Testing, waiver and test-article rationale: how each question will be addressed and why the selected article represents the finished product.
10. Risk-management traceability: links to hazards, controls, gaps, decisions, owners and the later BER conclusion.
11. Lifecycle triggers: formulation, supplier, process, packaging, shelf-life, claim, use or regulatory changes that require re-evaluation.

This is a content framework, not a ready-made test prescription. The general Biological Evaluation Plan guide explains how planning differs from the final BER and when a builder, drafting service or independent review is proportionate.

Patient-Contact and Reprocessing Wipes Need Different Plans

A wipe placed directly on a patient presents a contact question about the finished wipe and the substance delivered at the use site. A device-processing wipe can create a patient-contact question about the device after processing and, where required by its intended purpose or device-specific controls, a separate non-patient user-safety question. The BEP should not treat these as interchangeable or imply that every worker-exposure issue falls within ISO 10993-1.

FDA's May 2026 DEN240075 decision created a Class II generic device type for an interim reprocessing cleaning and intermediate-level disinfection wipe. It is a non-terminal step before terminal reprocessing; it must not change or replace the reusable-device manufacturer's validated reprocessing instructions. The decision identifies controls relating to user biocompatibility of the wipe and patient biocompatibility of the processed devices, alongside cleaning, disinfection, subsequent reprocessing, material compatibility, shelf life, human factors and labeling. This defined type is not exempt from premarket notification under section 510(k), and the decision should not be applied to every disinfectant wipe.

For reprocessing claims, align the BEP with validated instructions and the FDA reprocessing guidance. The reusable-instrument guide provides a wider view of residues, repeated cycles and representative states.

Build Chemistry and Residue Logic Before Ordering Tests

A wipe formulation can contain volatile and non-volatile components, preservatives, surfactants, impurities, degradation products and substrate-related substances. The key question is not merely what is present in the formulation, but what can reach the patient or an applicable non-patient user under actual and worst-case use.

For a processed device, document application amount, surface area, wipe-to-device transfer, evaporation, rinsing, drying, subsequent cleaning or sterilization, number of cycles, and the device's later contact with the patient. Chemistry and exposure information can help decide whether an existing evidence package is sufficient, whether a toxicological assessment is needed, and which gaps genuinely require testing.

Select a Representative or Worst-Case Test Article

If testing is justified, the article must represent the biological question. Consider formulation concentration, substrate, liquid loading, manufacturing site or process, sterilization, packaging, aging, dry-out, extraction conditions, and the use stage that creates maximum relevant exposure. For a wipe used on another device, the test article may need to represent the processed device after the specified wiping and subsequent reprocessing sequence—not only an unused wipe.

The test-article preparation guide explains how to connect final-finished-device logic, sterilization, aging and specimen preparation to the test record. Endpoint decisions should then follow the risk-based endpoint-selection framework.

Keep Three Evidence Questions Separate

• Biological safety: can the finished wipe or transferred residues create an unacceptable biological risk for the patient or, where applicable, a non-patient user?
• Cleaning or disinfection performance: does the wipe achieve the claimed performance under validated use conditions?
• Material compatibility: can repeated use damage the processed device, its coatings, seals, optics, electronics or functional performance?

These questions interact, but evidence for one does not automatically answer the others. For example, microbial efficacy does not establish biological safety, and a material-compatibility result does not quantify patient exposure to residues.

Common Medical-Wipe BEP Mistakes

• starting with a fixed cytotoxicity, sensitization and irritation package before defining exposure
• evaluating ingredients individually while omitting the final substrate–formulation–packaging system
• failing to determine whether healthcare-worker exposure is governed by personal-protection scope, device-specific controls or separate occupational-safety requirements
• assuming that evaporation removes all relevant transferred residue
• using an unused wipe as the only article when the biological question concerns a processed device
• combining biological safety, disinfectant efficacy and material compatibility into one vague conclusion
• citing DEN240075 as though it classifies every medical or disinfectant wipe
• failing to define re-evaluation triggers for formulation, loading, supplier, packaging or use changes

Medical-Wipe BEP Review Checklist

• Is the intended purpose and regulatory status stated for every target market?
• Are patient, user and processed-device exposure routes mapped separately?
• Does the device description cover substrate, complete formulation, loading, processing, packaging, aging and use conditions?
• Are transferred residues and cumulative cycles considered where another device is wiped?
• Does each biological question link to applicable evidence, a justified gap or a planned action?
• Are test-waiver and representative-article rationales explicit rather than implied?
• Are biological safety, performance and material-compatibility conclusions kept distinct?
• Can the BEP trace its decisions into risk management and the later BER?
• Are lifecycle change triggers and decision owners defined?

Frequently Asked Questions

Limits of This Guide

This guide is educational and does not provide a product classification, device-specific test plan, regulatory determination, legal opinion or assurance of authority acceptance. Standards, recognition conditions, guidance and classifications change. Verify current controlled sources for each target market and use appropriately qualified biological-safety, toxicology, reprocessing and regulatory expertise.